Paick Jae-Seung, Kim Soo Woong, Ku Ja Hyeon
Department of Urology, Seoul National University Hospital, 28 Yongon-Dong, Jongno-Gu, Seoul, Korea.
Yonsei Med J. 2007 Apr 30;48(2):281-8. doi: 10.3349/ymj.2007.48.2.281.
We have evaluated the patterns of diagnostic and treatment practices for benign prostatic hyperplasia (BPH) in a country that does not have country-specific clinical practice guidelines.
Probability samples were taken from the Korean Urological Association Registry of Physicians, and randomly sampled Korean urologists were asked to complete a questionnaire. The survey explored practice characteristics and attitudes, as well as diagnostic and treatment strategies, for the management of BPH.
Of the 850 questionnaires sent, 302 were returned, and 277 of those were included in the final analysis (response rate 32.6%). For the initial evaluation, most urologists routinely used digital rectal examinations (DRE) and urinalysis. Uroflowmetry was used 34.7% of the time. Pressure-flow studies were rarely done. Symptom assessment was used in only 46.9% of cases. In addition, a significant number (58.8%) reported that treatment decisions were not based on the symptom questionnaire. Before surgery, almost all urologists routinely used DRE, urinalysis, and prostate-specific antigen tests. Of the respondents, 55.6% and 41.9% had prescribed alpha- blockers and alpha-blockers with 5-alpha reductase inhibitors, respectively. 81.2% of urologists perceived that selective alpha-blockers are different in terms of efficacy, and 82.7% felt that they differed in safety. Most respondents prescribed 5-alpha reductase inhibitors based on the prostate size.
These data provide a picture of current practices regarding the management of BPH in Korea. The diagnostic and treatment practices for BPH do not follow published guidelines. Our findings ask the question "How influential are international guidelines, and do they really affect patient management in countries that do not have country-specific guidelines?"
我们评估了在一个没有特定国家临床实践指南的国家中,良性前列腺增生(BPH)的诊断和治疗模式。
从韩国泌尿外科学会医师登记处抽取概率样本,随机抽取的韩国泌尿外科医生被要求填写一份问卷。该调查探讨了BPH管理的实践特征和态度,以及诊断和治疗策略。
在发放的850份问卷中,回收了302份,其中277份纳入最终分析(回复率32.6%)。对于初始评估,大多数泌尿外科医生常规使用直肠指检(DRE)和尿液分析。尿流率测定使用了34.7%的时间。压力-流率研究很少进行。仅46.9%的病例进行了症状评估。此外,相当数量(58.8%)的医生报告称治疗决策并非基于症状问卷。手术前,几乎所有泌尿外科医生常规使用DRE、尿液分析和前列腺特异性抗原检测。在受访者中,分别有55.6%和41.9%的医生开具了α受体阻滞剂和α受体阻滞剂联合5α还原酶抑制剂。81.2%的泌尿外科医生认为选择性α受体阻滞剂在疗效方面存在差异,82.7%的医生认为它们在安全性方面存在差异。大多数受访者根据前列腺大小开具5α还原酶抑制剂。
这些数据描绘了韩国目前BPH管理的实践情况。BPH的诊断和治疗实践未遵循已发表的指南。我们的研究结果提出了一个问题:“国际指南有多大影响力,它们真的会影响那些没有特定国家指南的国家的患者管理吗?”